How to Fix Non-Restorative Sleep: Labs and Next Steps

What Non-Restorative Sleep Actually Means

NRS is the persistent feeling of waking unrefreshed regardless of how many hours you spent asleep. It is not simply "bad sleep." The International Classification of Sleep Disorders, Third Edition (ICSD-3) previously listed NRS as a standalone insomnia subtype before folding it into the broader insomnia disorder category, but the complaint itself is treated as clinically distinct and appears to predict daytime impairment independently of sleep duration [1].

A large cross-sectional survey of adults across the general European population found that roughly 1 in 10 respondents reported non-restorative sleep on most nights over the prior month, and fewer than half of them also met criteria for insomnia [2]. In plain terms, most people with NRS are not lying awake or waking repeatedly. They get enough hours. The architecture of that sleep is the problem.

That distinction is worth separating from a more familiar public health issue: national survey data compiled by the CDC show a large share of US adults do not consistently get 7 or more hours of sleep in the first place [https://www.cdc.gov/mmwr/volumes/65/wr/mm6506a1.htm]. Short sleep duration and non-restorative sleep are different problems with different workups. This article is about the second one - people who are getting enough time in bed and still waking up tired.

Researcher Harvey Moldofsky, who first described alpha-EEG sleep anomalies in the 1970s, framed NRS as a disruption in the microstructure of sleep - the fine-grained pattern of brainwave activity within a sleep stage - rather than its macrostructure, meaning total time asleep or how many times someone wakes [3]. That framing matters for what to do next. Standard sleep hygiene advice targets macrostructure (time in bed, consistency, light exposure). NRS often needs a look at what is fragmenting deep sleep at a level basic sleep hygiene cannot fix.

People with NRS report higher rates of chronic pain, fatigue, cognitive complaints, and mood disturbance than people who sleep the same number of hours and feel refreshed [2]. It is a clinical signal worth investigating, not a subjective nuisance to push through.

Common Causes and Contributing Conditions

The differential for NRS spans endocrine, inflammatory, psychiatric, and primary sleep disorders. Narrowing it down takes both lab work and clinical history - no single test rules NRS in or out.

Thyroid dysfunction is among the most frequently missed contributors. Subclinical hypothyroidism (an elevated TSH with a normal free T4) has been linked to reduced slow-wave sleep in polysomnographic studies, with patients presenting adequate sleep duration but profound morning fatigue [4]. A TSH alone can miss the picture; free T4 and thyroid peroxidase antibodies add clarity when TSH sits in the upper-normal range.

Iron deficiency without anemia is another common and correctable contributor. Low ferritin has been associated with periodic limb movements during sleep (PLMS), which fragments sleep architecture without necessarily causing full awakenings the patient remembers [5]. Consensus guidelines for iron treatment in restless legs syndrome and PLMS use a ferritin target above 75 ng/mL before considering iron repletion complete, well above the lower limit most labs flag as "normal" [5].

Obstructive sleep apnea (OSA) can produce NRS even at mild severity. Cohort data from long-running sleep research suggest people with a mild apnea-hypopnea index (AHI 5 to 14 events per hour) report unrefreshing sleep more often than people without OSA, though the exact size of that effect varies by study and is worth confirming against the primary literature rather than treating as a fixed number [6]. Many of these patients do not snore loudly or notice breathing pauses. They simply never consolidate deep sleep.

Other conditions worth screening for include depression (which suppresses slow-wave sleep and alters REM timing), fibromyalgia (frequently comorbid with NRS in rheumatology settings), chronic low-grade inflammation measurable via high-sensitivity CRP, and poorly controlled type 2 diabetes, where nocturnal glucose swings can disrupt sleep continuity [7].

Lab Tests Your Clinician Should Order

A reasonable first-pass NRS panel targets the reversible metabolic and inflammatory causes that most commonly fragment sleep architecture. No single lab confirms NRS, but an abnormal result directs treatment.

Thyroid panel: TSH, free T4, and TPO antibodies. Even a "normal" TSH above roughly 3.0 mIU/L in a symptomatic patient is worth a conversation about further workup, since the upper limit of the normal range remains debated among endocrinology societies [8].

Iron studies: Serum ferritin, serum iron, TIBC. Consensus guidelines use a treatment target above 75 ng/mL for patients with restless legs symptoms or PLMS, not the lower cutoff many labs print as normal [5].

Complete metabolic panel (CMP): Screens for renal and hepatic dysfunction, electrolyte abnormalities (low magnesium in particular can disrupt GABA-mediated sleep), and glucose dysregulation.

HbA1c: Values of 5.7 percent or above suggest prediabetic glucose variability, which has been linked to nighttime glucose swings that can fragment deep sleep [7].

25-hydroxyvitamin D: Low vitamin D is associated with worse subjective sleep quality across pooled data from multiple studies, though vitamin D correction alone will not fix NRS that has another primary cause [9].

Morning cortisol (drawn between 7:00 and 9:00 AM): A value well below or well above the reference range warrants further evaluation for adrenal insufficiency or Cushing syndrome, respectively. Both can produce NRS through different mechanisms.

High-sensitivity CRP: Elevation above 3.0 mg/L without acute infection suggests chronic low-grade inflammation, which population studies link to reduced slow-wave sleep [10].

CBC with differential: Screens for anemia and flags eosinophilia or other markers that might point to allergic or parasitic causes of sleep disruption.

If these labs come back normal and symptoms persist beyond about four weeks, the next step is a formal sleep study.

Deciding What to Do Next: A Simple Framework

The diagnostic approach to non-restorative sleep varies depending on individual circumstances and clinical presentation. Use the table below to guide your discussion with a clinician, but it should not replace personalized clinical assessment.

When a Sleep Study Is Warranted

Polysomnography (PSG) becomes the priority when the lab panel is unremarkable and NRS has persisted for more than about a month. A home sleep apnea test (HSAT) is adequate for ruling out moderate-to-severe OSA but misses milder cases and cannot assess sleep architecture the way in-lab PSG can.

In-lab testing is generally preferred over a home test when periodic limb movement disorder, narcolepsy, or a parasomnia is suspected alongside NRS, since PSG measures sleep stages, respiratory events, limb movements, and EEG activity simultaneously - this is where an alpha-delta intrusion pattern becomes visible.

Sleep-referral cohorts have found that a meaningful share of patients with NRS and normal screening labs receive a diagnosable finding on PSG, commonly OSA, periodic limb movement disorder, or an alpha-delta pattern, though exact proportions differ across the published studies and any single percentage should be checked against its original source before being treated as a hard number [11].

Actigraphy (a wrist-worn motion sensor worn for 7 to 14 days) adds useful data on circadian rhythm alignment and night-to-night variability. It does not replace PSG but helps quantify how fragmented the sleep-wake pattern is across multiple nights.

The Alpha-Delta Sleep Pattern

Alpha-delta sleep, first described by Moldofsky and colleagues in 1975, is the intrusion of alpha-frequency EEG activity (8 to 13 Hz) into the delta-wave (0.5 to 4 Hz) epochs that define stage N3 deep sleep [3]. The brain overlays a waking rhythm on its deepest restorative phase. Patients with this pattern spend time in "deep sleep" that is not functionally deep.

This finding is most studied in fibromyalgia, where it appears in a majority of patients and is strongly associated with the NRS complaint [12]. It also shows up in chronic fatigue syndrome, major depression, and rheumatoid arthritis. It is not specific to any one disease, but its presence confirms an objective disruption of sleep quality that standard metrics like total sleep time and sleep efficiency would miss entirely.

Treatment of alpha-delta sleep targets the underlying condition. In fibromyalgia, a randomized, placebo-controlled trial of low-dose pregabalin found greater improvement in subjective sleep quality compared with placebo, alongside reduced pain scores [13]. Sodium oxybate has also shown efficacy for alpha-delta intrusions in research settings, but its use is restricted due to abuse potential and it is generally reserved for narcolepsy with cataplexy, not prescribed for NRS alone.

Treatment Approaches That Address Root Causes

The most effective intervention for NRS is correcting the underlying driver. There is no single "NRS drug." Treatment follows the diagnosis.

Hypothyroidism: Levothyroxine titrated to a target TSH typically improves sleep quality scores over roughly 8 to 12 weeks. Reviews of hypothyroidism's cognitive and psychiatric effects describe meaningful improvement in sleep-quality measures after TSH normalization, though the exact magnitude varies by study population [4].

Iron deficiency: Oral iron supplementation, often dosed every other day for better absorption, targets a ferritin above 75 ng/mL. PLMS frequency typically declines within 6 to 8 weeks of reaching that target [5]. Intravenous iron is appropriate when oral supplementation fails or ferritin remains below 30 ng/mL despite adherence.

OSA: Continuous positive airway pressure (CPAP) remains the standard treatment. A Cochrane review of CPAP trials found improvement in subjective sleep quality, with effects reported as most pronounced in patients whose primary complaint was unrefreshing sleep rather than daytime sleepiness [14]. Mandibular advancement devices are a reasonable alternative for mild-to-moderate OSA when CPAP adherence is poor.

Vitamin D deficiency: Supplementing to bring 25-OH vitamin D into a normal range has improved sleep quality scores in randomized trials of adults with clear baseline deficiency, though vitamin D is unlikely to help NRS in someone who is not actually deficient [9].

Depression: SSRIs can worsen NRS by suppressing slow-wave sleep. When NRS is the dominant sleep complaint in a depressed patient, clinicians sometimes favor agents with sedating properties and less slow-wave sleep disruption, such as mirtazapine, based on polysomnographic data showing increased slow-wave sleep with that class of medication [15].

Medications With Evidence for NRS

When the underlying cause has been treated or ruled out and NRS persists, pharmacotherapy targets sleep architecture directly. Short courses are generally preferred, and the right choice depends on what else is going on.

Trazodone (25 to 100 mg): Widely used off-label for sleep in the United States. It appears to increase slow-wave sleep without suppressing REM [15]. Formal insomnia-trial evidence is limited, but PSG data and decades of clinical use support it for NRS when reduced N3 sleep looks like the main deficit.

Suvorexant (Belsomra, 10 to 20 mg): A dual orexin receptor antagonist that promotes sleep by blocking wakefulness signals rather than sedating broadly. Trial data show improved subjective sleep quality and next-day functioning compared with placebo [16].

Gabapentin (100 to 300 mg at bedtime): Increases slow-wave sleep in PSG studies and is particularly useful when NRS coexists with neuropathic pain or restless legs [13]. The sleep-promoting dose sits well below the analgesic range, which limits side effects.

Lemborexant (Dayvigo, 5 to 10 mg): Another orexin antagonist. The SUNRISE-2 trial, which followed nearly 950 adults with insomnia disorder, found that lemborexant improved sleep efficiency and reduced time awake after sleep onset compared with placebo over six months, with effects sustained and no rebound insomnia after stopping [17].

Benzodiazepines are generally avoided for NRS specifically, since they suppress slow-wave sleep and can worsen the architectural deficit that defines the condition.

Behavioral and Lifestyle Interventions

Cognitive behavioral therapy for insomnia (CBT-I) is the treatment with the strongest guideline backing for chronic insomnia, and its core principles apply directly to NRS. Sleep restriction therapy, the most active component of CBT-I, works by compressing the sleep window, which increases sleep pressure and consolidates deep sleep that would otherwise be diluted across too many hours in bed.

A randomized trial of adults with insomnia and NRS found that structured CBT-I sessions improved the "feeling refreshed on waking" component of a standard sleep-quality questionnaire more than sleep hygiene education alone, with gains that persisted at 12-month follow-up - a durability that medications rarely match once stopped [18].

The American Academy of Sleep Medicine's 2021 guideline on behavioral and psychological treatments for chronic insomnia recommends CBT-I as first-line therapy for adults with chronic insomnia disorder [18].

Practical behavioral targets include a consistent wake time seven days a week (the strongest circadian anchor available), limiting time in bed to actual sleep time plus about 30 minutes, avoiding alcohol within about 4 hours of bedtime (alcohol fragments N3 sleep in the second half of the night), and reducing evening light exposure in the two hours before the target sleep time.

When to Escalate Care

Ask for a referral to a sleep medicine specialist if NRS persists after about 8 weeks of treating identified lab abnormalities and trying CBT-I principles. Refer sooner if cataplexy, sleep paralysis, or hypnagogic hallucinations are present, since these suggest narcolepsy. Seek prompt follow-up if a sleep study shows an AHI above 30 events per hour or oxygen desaturation below 85 percent.

Patients with fibromyalgia-associated NRS who do not respond to pregabalin or gabapentin may be candidates for a rheumatology referral to discuss other options; low-dose naltrexone has shown preliminary, small-trial signal for fibromyalgia sleep quality, but the evidence base is limited and this is not a first-line recommendation. During iron repletion, recheck ferritin roughly every three months and aim for a sustained level above 75 ng/mL before attributing residual NRS to a cause other than iron.

A ferritin of 22 ng/mL is often flagged as "normal" on a standard lab report but sits well below the treatment target sleep medicine uses. A TSH of 4.2 mIU/L can fall inside a lab's printed reference range and still represent early thyroid dysfunction in a symptomatic person. Asking for the right labs, read against sleep-specific thresholds rather than generic reference ranges, is often the highest-yield step for anyone with persistent non-restorative sleep.